Celebrating the era of smart blood sugar control with Continuous Glucose Monitoring (CGM)

The market for modern health monitoring devices is rapidly developing worldwide. What is your vision of the current situation?

Indeed, the demand for such solutions is growing rapidly. Our company, MLC GT, with the help of a group of technology partners, has developed our original continuous glucose monitoring (CGM) system technology that fully meets the current market demands.

Ivan Saltanov
CEO of MLC GT

How CGM Works

Continuous glucose monitoring (CGM) devices help manage glucose levels in diabetic patients by reducing the number of fingerstick tests. A sensor placed directly and minimally invasively measures glucose levels 24 hours a day.

The sensor sends results to a wearable device or mobile phone, allowing you to track changes in your blood glucose levels in real time. CGM application is rapidly spreading worldwide due to its ease of use and 24/7 glucose monitoring.

Today, continuous glucose monitoring systems are already the new standard in diabetes management. According to the International Diabetes Federation, 589 million people worldwide have been diagnosed with diabetes, and this number continues to grow, shaping enormous and sustainable demand.

I see the current situation as the birthplace of a new global industry that will only grow stronger in the coming decades.

What role does the United Arab Emirates play in this process?

Our company views the United Arab Emirates as a strategic location for production and distribution worldwide. The best conditions for high-tech projects have been created here: developed infrastructure, convenient logistics, and access to international markets. Furthermore, the UAE government actively supports medical innovation, which will allow us to quickly scale up the production and launch the product in various countries.

What stage is the company at now?

We’ve already accomplished the most important thing: we’ve developed our original continuous glucose monitoring system. The product is now ready and undergoing certification. Next, we plan to launch production in the UAE and build a production line in Abu Dhabi.

How will the project be implemented?

As developers, we will work with our technology partners to implement our technologies and standards to make sure production immediately meets world-class standards.

We are also in negotiations and planning to attract a strategic investor to fully fund the construction and scale up our production. MLC GT will act as the operator of the production project.

What objectives does building a plant in the UAE address?

The main goal is to make high-quality and accurate glucose monitoring systems accessible to residents of the Middle East and neighboring countries. The UAE plant will make it possible for us to supply products directly to the region, rather than transporting them thousands of kilometers. For us, this is more than just a production facility, it’s an opportunity to meet the region’s needs for modern health diagnostics.

How do you see further development?

Our company, MLC GT, has quickly grown from a tech startup into an established company. In the next 10 years, we see our project becoming a leader in health monitoring. We plan to expand into new markets and make high-quality diagnostics accessible to everyone, regardless of where they live.